Leading the Stem Cell Revolution

The “stem cell” discovery by Dr. Arnold Caplan = 1st approved stem cell drug
27,000

Citations for Osiris’ foundational paper

$660 Million

Sale price of Osiris’ cellular matrix product line

Over 1000

Medical conditions are being tested with MSC treatment

  • Discovery

    Mesenchymal stem cells (MSCs) orchestrate healing throughout the body.

  • Innovation

    Dr. Arnold Caplan, Jim Burns, Peter Friedli, and Kevin Kimberlin formed Osiris Therapeutics to develop MSC-based therapies.

  • Impact

    Osiris obtained the composition of matter patent on the MSC and characterized it in a Science paper that has been cited more than any other in the history of medicine.

    This is a result of over 1,700 clinical studies registered with Clinical Trials.gov, covering 1,338 conditions, a scope unprecedented in the pharmaceutical industry.

    As the leader in cellular regeneration, Osiris brought the first approved MSC drug to market in the U.S. and also obtained the first regulatory approval for an MSC drug.

    Other products became standards of care, including Osteocel, the first product in the U.S. market containing MSCs, and Grafix – with a 71% healing rate for non-healing diabetic foot ulcers, the leading cause of amputation.

    Osiris sold Osteocel for $50 million, sold its MSC portfolio to Mesoblast for $100 million in cash, equity, and royalties, before the firm was acquired by Smith and Nephews for $660 million. Most importantly, the firm’s products have saved thousands of lives.

“Kevin Kimberlin is a man who has a passion for aggregating resources for causes that have a really important goal.”

The Science of MSCs with Dr. Arnold Caplan
Dr. Arnold Caplan with Kevin Kimberlin
MSCs